STREAM is a collaboration of researchers who share a common set of principles about the goals and methods for studying clinical translation. We apply empirical and philosophical tools for addressing scientific, ethical, and policy challenges in the development and translation of health technologies. Our members work in ethics, epidemiology, biology, psychology, and various medical specialties. The network is centered at McGill University, and has affiliates throughout North America and abroad.
Carlisle B, Federico C, Kimmelman J. Trials that say “maybe”: the disconnect between exploratory and confirmatory testing after drug approval, The BMJ, March 20, 2018.
Marcin Waligora, Malgorzata M. Bala , Magdalena Koperny, Mateusz T. Wasylewski, Karolina Strzebonska, Rafał R. Jaeschke, Agnieszka Wozniak, Jan Piasecki, Agnieszka Sliwka, Jerzy W. Mitus, Maciej Polak, Dominika Nowis, Dean Fergusson, Jonathan Kimmelman. Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis. PLoS Medicine. February 2018.
Jonathan Kimmelman quoted in Medical Republic article on animal studies and translational research.
Can cancer researchers accurately judge whether preclinical reports will reproduce? described as one of the biggest media hits at PLoS Bio for 2017.
Jonathan Kimmelman in Bloomberg News article about CRISPR.
STAT News coverage of recent research from Jonathan Kimmelman and colleagues showing that cancer experts are not very accurate at forecasting results of clinical trials.
Jonathan Kimmelman quoted in CBC News: "Should we let the crowd fund Canadian science if no one else will?"
Jonathan Kimmelman quoted in STAT News: "Tiny human brain organoids implanted into rodents, triggering ethical concerns"
Jonathan Kimmelman quoted in Health News Review: "In need of scrutiny: Misleading stem cell claims by academic medical centers"
Jonathan Kimmelman quoted in MIT Technology Review: "Artificial Human Embryos Are Coming, and No One Knows How to Handle Them"
Jonathan Kimmelman quoted in Reuters Health: "Discrepancy between trial goals, results may mask treatment risks"